Catalpol: A Potential Therapeutic for Neurodegenerative Diseases

Author(s): B. Jiang, R.F. Shen, J. Bi, X.S. Tian, T Hinchliffe, Y. Xia

Journal Name: Current Medicinal Chemistry

Volume 22 , Issue 10 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer


Neurodegenerative disorders, e.g., Alzheimer’s disease (AD) and Parkinson’s disease (PD) are characterized by the progressive loss of neurons and subsequent cognitive decline. They are mainly found in older populations. Due to increasing life expectancies, the toll inflicted upon society by these disorders continues to become heavier and more prominent. Despite extensive research, however, the exact etiology of these disorders is still unknown, though the pathophysiological mechanisms have been attributed to oxidative, inflammatory and apoptotic injury in the brain. Moreover, there is currently no promising therapeutic agent against these neurodegenerative changes. Catalpol, an iridoid glucoside contained richly in the roots of the small flowering plant species Rehmannia glutinosa Libosch, has been shown to have antioxidation, anti-inflammation, anti-apoptosis and other neuroprotective properties and plays a role in neuroprotection against hypoxic/ischemic injury, AD and PD in both in vivo and in vitro models. It may therefore represent a potential therapeutical agent for the treatment of hypoxic/ischemic injury and neurodegenerative diseases. Based on our studies and those of others in the literature, here we comprehensively review the role of Catalpol in neuroprotection against pathological conditions, especially in neurodegenerative states and the potential mechanisms involved.

Keywords: Catalpol, neurodegenerative disease, neuroprotection, oxidant stress, inflammation, mitochondria, NF-κB, neurotrophins.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [1278 - 1291]
Pages: 14
DOI: 10.2174/0929867322666150114151720
Price: $65

Article Metrics

PDF: 57